We investigated the mechanism underlying the effect of a combination treatment of 
I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2α-ATF4-CHOP pathway Introduction Hepatocellular carcinoma (HCC) is the third most common malignant cancer in China and has a serious negative effect on patient's health. More than three million people die from HCC every year in China, especially in rural areas 1 . For inoperable HCC patients, radiotherapy (RT) alone does not improve the overall survival. Recently, 125 I seed implantation has been proven to be a safe, efficacious, and economical method for treating moderate and advanced HCC. However, RT when combined with other treatments, such as platinum chemotherapy, exhibits a better prognosis than the non-RT therapies 2, 3 . Due to the mechanisms underlying the effects of 125 I seed in HCC and enhancement of the radiosensitivity of HCC to 125 I seed by chemotherapy are unclear, identification of new cellular targets of 125 I seed would lay a solid foundation for better clinical application of 125 I seed implantation therapy and would provide novel therapeutic approaches for treating HCC.
Endoplasmic reticulum (ER) is an important organelle in cells. Damage of its function causes stress reaction in ER, which is known as ER stress. ER protects cells from the damage caused by such stress, by activating the unfolded protein response (UPR) 4, 5 . The UPR relies on the duration of exposure of cells to unfavorable conditions, such as radiation, which may have disparate outcomes, such as adaptation to the stress or apoptosis 6 . A proper UPR aims to reduce the ER capacity and protein synthesis, causing the cells to adapt to the stress. However, in the event of an insufficient adaptive response, ER stress induces cells to go through apoptosis and regulates C/EBP homologous protein (CHOP), JNK activation, and Bcl-2 expression 7 . The PERK-eIF2α-ATF4-CHOP pathway plays an important role in ER stress; it induces apoptosis through upregulation of CHOP, Bcl-2, and other apoptosis-related factors.
As a third-generation platinum drug, lobaplatin (LBP) is reported to induce apoptosis and cell cycle arrest, and impairs the migration and invasion in various gastrointestinal tumor cell lines in vitro 8, 9 . Cells at the G2/M transition stage are more sensitive to RT, indicating that LBP might enhance the radiosensitivity of HCC and ultimately decrease the biologically effective dose, serving to reduce RT-related complications 10, 11 . A retrospective study showed that transarterial chemoembolization (TACE) with gelatin sponge microparticles mixed with LBP is a safe and effective method for stage B HCC patients 12 . Moreover, Peng et al. 13 reported that the combination of LBP-TACE and brachytherapy has a better overall survival than that of LBP-TACE alone; thus, a comprehensive therapy is recommended for these patients 13 . Based on the results of isobaric tag for relative and absolute quantification labeling (iTRAQ) and the function of PERK-eIF2α-ATF4-CHOP pathway, we hypothesized that 125 I seeds might induce the upregulation of PERKeIF2a-ATF4-CHOP pathway, resulting in apoptosis in liver cancer cells. Moreover, we verified that LBP could enhance the apoptosis and anti-proliferative activity of 125 I, and assumed that this enhancement might work by regulating the PERK-eIF2α-ATF4-CHOP pathway. To test these hypotheses, the correlation between 125 I and PERK-eIF2α-ATF4-CHOP pathway was evaluated in liver cancer cell lines and mice tumor model. We found that the PERK-eIF2α-ATF4-CHOP pathway was inhibited in liver cancer cells after treatment with 125 I and LBP. Our results indicate that 125 I induces the upregulation of PERK-eIF2a-ATF4-CHOP pathway to promote apoptosis and LBP promotes 125 I-induced apoptosis by increasing the 125 I-induced upregulation of PERK-eIF2α-ATF4-CHOP pathway. In summary, our data identify PERKeIF2a-ATF4-CHOP pathway as a new mechanism of apoptosis induced by 125 I and suggest that PERK-eIF2a-ATF4-CHOP pathway could be a new therapeutic target in 125 I seed implantation therapy for HCC.
Materials and methods

Mice subcutaneous tumor formation assay
For xenograft tumor studies, 100 μl of SMMC7721 cells (1 × 10 7 /ml) transfected with PERK-RNAi or ControlRNAi were diluted in 0.9% saline solution and injected subcutaneously in the hind leg of BALB/c male mice (purchased from the Animal Research Center of Shandong University). When the volume of tumor reached 500 mm 3 , the mice were randomly divided into three group with four mice in each group. Tumor diameters and weight were measured every other day for 30 days, at which time mice were killed and tumors were excised, measured, and lysed for RNA isolation. All mice were housed under specific pathogen-free conditions and were killed according to regulations formulated by the Shandong University Animal Care Committee.
Procedure for radioactive 125 
I seeds implantation in mice
First of all, the skin on the surface of the tumor was sterilized with iodine. After local anesthesia with lidocaine, the subcutaneous tumor was punctured with an 18G needle (Kakko, Japan) under direct vision. The endpoint of the needle was located at the middle of the tumor. The seed was advanced into the tumor through the needle using seed implantation equipment (Ningbo Junan Pharmaceutical Technology Company, Nanjing, China). When the procedure was completed, a sterile gauze was pressed to stop the bleeds, if necessary.
Radiation for HCC cell lines
125 I seeds were purchased from Ningbo Junan Pharmaceutical Technology Company (Ningbo, Zhejiang, China).
125 I seeds were seeded into an in vitro irradiation model, based on a previous method 14 . The initial activity and dose rate were 3.0 mCi and 3.412 cGy/h, respectively. To deliver doses of 1, 2, and 4 Gy, irradiation times of 29.3, 58.6, and 117.2 h, respectively, were used.
Cell lines and transfection
The HCC cell lines were purchased from the Chinese Academy of Sciences (Shanghai, China). The cells were incubated in 5% CO 2 at 37°C and grown in culture media supplemented with 10% fetal calf serum (Gibco, Waltham, MA USA). Human HCC cell line HepG2 was cultured in Dulbecco's modified Eagle's medium (DMEM; Corning, Inc., Corning, NY, USA). Human HCC cell line SMMC7721 was cultured in RPMI 1640 (Corning, Inc., Corning, NY, USA).
Transfections were performed using Lipofectamine 2000 (Invitrogen, CA, USA) according to the manufacturer's instructions. A short interfering RNA (siRNA) for PERK (protein kinase RNA-like ER kinase) was designed by RiboBio (Guangzhou, Guangdong, China). PERK-RNAi was purchased from Genechem (Shanghai, China).
iTRAQ labeling
HepG2 cells were treated with or without 125 I and total protein was isolated with RIPA (TIANGEN). The iTRAQ was performed by Jiyun Biotech (Shanghai, China) in 125 Itreated HepG2 cells and control HepG2 cells. The signal pathway enrichment was analyzed using Ingenuity Pathway Analysis (INGENUITY). The mean value between the 125 I-treated group and control group, which is >1.2 and p < 0.05, is supposed to be significantly upregulated.
Selection for sensitizing concentration of LBP to HCC cells HCC cells were seeded in a 96-well plate. After treatment with concentrations of LBP ranging from 0 to 80 µg/ mL for 72 h, the optical density was detected using CCK-8 assays (Dojindo, Kumamoto, Japan). The half-maximal inhibitory concentration (IC 50 ) was calculated with Prism 6.0 (GraphPad, San Diego, CA, USA). According to the toxic effects of LBP on HCC cells and previously published method, the LBP-sensitizing concentration was determined to be 10% of the IC 50 15 .
Cell proliferation assay
After treatment, cells were collected as a single cell suspension and were seeded in 96-well plates at 5 × 10 3 cells/well, with each well containing 200 µL culture medium. The CCK-8 reagent was added into the medium at 24, 48, and 72 h after the cell was attached and then incubated at 37°C for 3 h. Finally, the plate was scanned by a microplate reader (Thermo, Waltham, MA, USA).
Cell cycle and apoptosis analysis
Cells were seeded into six-well plates at 2 × 10 5 cells per well and were treated as indicated. For the cell cycle assay, after collection, the cells were washed with cold phosphate-buffered saline (PBS), fixed with 70% cold ethanol, and stored at −4°C overnight. Before analysis, the cells were stained with propidium iodide (PI) and RNase A (BD Biosciences, Franklin Lakes, NJ, USA). For the apoptosis analysis, after collecting, cells were either stained with PI and Annexin V-FITC (BD Biosciences) or Annexin V-APC (Elabscience, Wuhan, China). Both the cell cycle and apoptosis assays were assessed using a flow cytometer (BD Biosciences).
Surviving fractions
After being treated as indicated, the cells were collected as a single cell suspension and were seeded in six-well plates at 10 3 cells/well, with each well containing 3 mL culture medium. After incubation on the plates for 10-14 days, the colonies were washed once with PBS, fixed with 4% paraformaldehyde for at least 1 h, and were stained with crystal violet for 30 min. Colonies containing more than 50 cells were counted in 3 replicate dishes. The surviving fraction (SF) was defined as the ratio of PE ( 125 I + LBP)/PE ( 125 I), with PE defined as (colony number/ number of seeded cells) × 100.
Terminal deoxynucleotidyl transferase dUTP nick end labeling assay
After treatment as indicated, the cells were washed once with 1 × PBS and treated with PBS containing 0.3% Triton X-100 for 5 min. Then, the cells were fixed in 4% paraformaldehyde for at least 1 h, stained with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reagent (Beyotime Biotechnology, Nanjing, Jiangsu, China) for 1 h at 37°C, and incubated with 4′,6-diamidino-2-phenylindole for another 15 min. Morphological changes were observed using a fluorescence microscope (Olympus, Tokyo, Japan). Three different fields were selected. Cells were counted using Image J.
EdU staining assay
The cell proliferation was detected using Cell-Light EdU Apollo567 In Vitro Kit (RiboBio, Guangdong, China) according to the manufacturer's instructions. After treatment, the cell medium was replaced with 50 μM EdU solution diluted with DMEM and incubated for 2 h. Hoechst 33342 was used to stain the nuclei and cell counting was done using a fluorescence microscope (Olympus, Tokyo, Japan). Cells were counted using Image J.
Western blotting and antibodies
After treatment as indicated, the cells were washed with cold 1 × PBS, lysed with RIPA lysis buffer for 20 min on ice, and centrifuged at 12,000 r.p.m. for 10 min at 4°C. Protein was denatured at 95°C for 5 min. Samples (20 µg each) were analyzed by 10-12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Millipore, Burlington, MA, USA). Membranes were blocked with 5% nonfat milk in Tris-buffered saline containing 1% Tween-20 for 1 h and incubated with corresponding primary antibodies at 4°C overnight. Then, the membranes were washed with Trisbuffered saline containing Tween-20 three times for 5 min each and incubated with corresponding secondary antibodies for 1 h at room temperature. Protein brands were detected by chemiluminescence (Millipore).
The primary antibodies anti-Bax (ab32503), anti-Bcl-2 (ab692), anti-ATF4 (ab184909), anti-CHOP (ab11419), anti-eIF2A (ab169528), anti-eIF2S (ab32157), and anti-PERK (ab79483) were purchased from Abcam (Cambridge, UK). Anti-phospho-PERK was purchased from Cell Signaling Technology (Beverly, MA, USA). The following secondary antibodies were purchased from GenScript (Piscataway, NJ, USA): goat anti-rabbit IgG (H&L), goat anti-mouse IgG (H&L), and rabbit anti-goat IgG. LBP was purchased from Changan Hainan International Pharmaceutical Co., Ltd (Haikou, Hainan, China).
RNA isolation and qPCR
Expression levels of PERK, eIF2a (eukaryotic initiation factor 2α), ATF4 (activating transcription factor 4), and CHOP were determined using quantitative real-time PCR. Total RNA was isolated from tissues and cultured cells using TRIzol reagent (TIANGEN, Beijing, China) according to the manufacturer's instructions. cDNA was synthesized from 1.0 μg RNA using a FastQuant RT Kit (TIANGEN). Quantitative PCR (qPCR) was performed by using BioRad C1000 Thermal Cycler CFX96 Real-Time System with SuperReal PreMix Plus (SYBR Green, TaKaRa). mRNA expression were normalized using detection of β-actin, respectively. Primers for qPCR were as follows: PERK, forward primer: 5′-ACGATGAGACAG AGTTGCGAC-3′, reverse primer: 5′-ATCCAAGGCAGC AATTCTCCC-3′; eIF2a, forward primer: 5′-CCGCT CTTGACAGTCCGAG-3′, reverse primer: 5′-GCAGTA GTCCCTTGTTAGTGACA-3′; ATF4, forward primer: 5′-ATGACCGAAATGAGCTTCCTG-3′, reverse primer: 5′-GCTGGAGAACCCATGAGGT-3′; CHOP, forward primer: 5′-GGAAACAGAGTGGTCATTCCC-3′, reverse primer: 5′-CTGCTTGAGCCGTTCATTCTC-3′; β-actin, forward primer: 5′-TCCCTGGAGAAGAGCTACCA-3′, reverse primer: 5′-AGCACTGTGTTGGCGTACAG-3′.
Statistical analysis
Data are reported as the mean ± SD. All experiments were repeated at least twice. GraphPad Prism software version 6.0 was used for statistical analysis. One-way analysis of variance with Tukey's multiple comparison test was utilized to analyze the subcutaneous tumor growth. An unpaired t-test was used when appropriate. *P < 0.05, **P < 0.01, and ***P < 0.001 were assumed.
Results
LBP increases 125 I-induced apoptosis in HCC cells
To investigate the radiosensitization effect of LBP on HCC cells to 125 I, the sensitization concentration of LBP was determined in HepG2 and SMMC7721 cell lines. The sensitization concentration was defined as 10% of the IC 50 . The CCK-8 assay suggested that LBP affected the viability of HepG2 and SMMC7721 cells in a dosedependent manner. The estimated IC 50 value of LBP at 117.2 h on HepG2 and SMMC7721 cells was found to be 5.972 µg/mL and 1.536 µg/mL, respectively (Fig. 1a) .
To estimate the radiosensitizing effect of LBP, HepG2 and SMMC7721 cells were exposed to 125 I, with and without concurrent treatment with LBP (Fig. 1b) . The SF Table 1 .
To investigate the promotion of 125 I-induced effects on cellular apoptosis by LBP, Annexin V-FITC/PI assay (Fig. 1c) and TUNEL assay (Fig. 1d) were performed in both HepG2 and SMMC7721 cells subjected to single or combined treatments. The Annexin V-FITC/PI assay revealed that when the HCC cells were treated with a combination of 125 I and LBP, cellular apoptosis was significantly higher than that observed when the cells were treated with 125 I or LBP alone (Fig. 1c) . Furthermore, TUNEL assay results showed that LBP increased the 125 Iinduced cellular apoptosis in both HepG2 and SMMC7721 cells (Fig. 1d) . The apoptosis was increased in the combination treatment group compared with that in the treatments with a single agent. Interestingly, the SMMC7721 cells showed more positive results than HepG2, which was consistent with the results of the radiosensitizing effect.
LBP promotes 125 I-induced anti-proliferative effect in HCC cells
To investigate whether the 125 I-induced anti-proliferative effect on HCC cells was promoted by LBP, a cell proliferation assay, cell cycle assay, and EdU assay were performed for both HepG2 and SMMC7721 cells treated with 125 I, LBP, or a combination of the two (Fig. 2) . Results of the cell proliferation assay suggested that the growth of HepG2 and SMMC7721 cells was inhibited following treatment with 125 I or LBP alone. However, the inhibition of cell growth was more significant in the combined treatment group (Fig. 2a) . Furthermore, the results of cell cycle analysis showed that both 125 I and LBP induced cell cycle arrest at the G2/M transition. In addition, the combined treatment resulted in more obvious cell cycle arrest (Fig. 2b) . Besides, results of the EdU assay showed that the combination treatment clearly exhibited fewer cells with proliferative status (Fig. 2c) .
125
I induces upregulation of the PERK-eIF2a-ATF4-CHOP pathway to promote apoptosis We hypothesized that 125 I radioactive seeds induce apoptosis and inhibit proliferation of HCC cells via multiple pathways, including regulation of apoptosis-related proteins (Fig. 3) . To test this hypothesis, iTRAQ was performed in control and 125 I-treated HepG2 cells. Among the differentially expressed proteins, we selected those involved in the eIF2 signaling pathway, which was the most enriched pathway. Furthermore, we identified the PERK-eIF2α-ATF4-CHOP pathway, a well-known ER stress pathway, to be potentially involved in 125 I-induced apoptosis (Fig. 3a) .
To confirm the relationship between 125 I and the PERKeIF2α-ATF4-CHOP pathway, pathway-related proteins were detected after HepG2 cells were treated with 125 I. The results of western blotting and qPCR demonstrated that the expression levels of the selected protein and mRNA were significantly increased in a dose-dependent manner (Fig. 3b, c) . Similar results were obtained in the mouse tumor model. The expression of the pathwayrelated genes was also upregulated at the mRNA level, as detected by qPCR (Fig. 3d) . Furthermore, to verify whether 125 I induces apoptosis through the PERK-eIF2α-ATF4-CHOP pathway, PERK-RNAi and Control-RNAi were transfected into HepG2 cells. After treatment with 125 I, a cell proliferation assay was performed to evaluate the effect of 125 I on anti-proliferation (Fig. 3e) . According to our results, the PERK-RNAi abrogated the 125 I-induced anti-proliferation effect. Apoptosis was detected by the Annexin V-FITC/PI assay. Compared with the cells transfected with Control-RNAi, the apoptosis rate was reduced in PERK-RNAi-transfected cells. Taken together, these data indicate that 125 I induces the upregulation of the ER stress pathway to promote apoptosis (Fig. 3f) . To further confirm the sensitizer role of LBP in 125 Imediated apoptosis and anti-proliferative effect in HCC cells, the PERK-eIF2α-ATF4-CHOP pathway-related proteins were detected after SMMC7721 cells were treated with 125 I or a combination of 125 I and LBP (Fig. 4a) . The results showed that the expression levels of the selected proteins were significantly increased in the combination treatment group compared with their levels in the group that was treated with 125 I alone. To verify the role of the PERK-eIF2α-ATF4-CHOP pathway in 125 I-mediated apoptosis and anti-proliferation, SMMC7721 xenograft tumors were treated with 125 I, LBP, and RNAi (PERK-RNAi and Control-RNAi). The results showed that, compared with the 125 I treatment alone, the combination treatment inhibited the tumor growth more significantly (Fig. 5) . As shown in the Fig. 5a , the combination of 125 I and LBP inhibited tumor growth more cooperatively than 125 I treatment alone. However, when the cells were transfected with PERK-RNAi, inhibition of tumor growth was reduced compared with that in the cells transfected with Control-RNAi. Consistent with the diminished growth curves, tumor weights at the time of killing were also significantly reduced in mice treated with the combined treatment compared with mice treated with 125 I alone (Fig. 5b) . Moreover, the tumor volume was more obviously decreased by the combined treatment than by treatment with 125 I alone (Fig. 5c) . In general, these data indicated that LBP promotes 125 I-induced antiproliferation in liver cancer cells. Overall, these results indicate that LBP increases the 125 I-induced upregulation of the PERK-eIF2α-ATF4-CHOP pathway to promote apoptosis and the inhibition of proliferation.
LBP increases the
Discussion
125 I seed implantation has recently become a standard treatment for the management of HCC 12, [16] [17] [18] . The risk of radiological complications is correlated with the dose, treatment volume, and dose rate 19 . A cardinal principle of 125 I seed implantation is to use the minimal dose, also known as the biologically effective dose, at which tumor cells are killed but neighboring normal cells are spared. 125 I on HepG2 and SMMC7721 cells. According to our results, the inhibition of cell growth was more significant in the combined treatment group than in the single treatment group. All experiments were performed in triplicate and the data are presented as the mean ± SD. The t-test was used for data analysis. *P < 0.05, **P < 0.01
Decreasing the total dose is a feasible method for preventing radiological complications. In a previous study, we showed that 125 I induces apoptosis and inhibits proliferation in pancreatic cancer cells 20 . However, the mechanism by which 125 I induces apoptosis and inhibits proliferation in HCC is still unknown. Based on the results of iTRAQ, eIF2 signaling pathway was found to be the most enriched pathway. We identified the PERKeIF2a-ATF4-CHOP pathway to potentially participate in 125 I-induced apoptosis. Here we investigated whether the radiosensitivity of HCC to 125 I could be promoted by LBP and the possible links between 125 I, LBP, and PERKeIF2α-ATF4-CHOP pathway.
LBP has been approved for the treatment of several cancers, including liver, stomach, lung, and nasopharyngeal cancers, and the combination of 125 I seeds and LBP results in improved prognosis in the treatment of hepatic cancer [21] [22] [23] . A retrospective study showed that TACE with gelatin sponge microparticles mixed with LBP is a safe and effective method for stage B HCC patients 12 .
Futhermore, it was reported that the combination of LBP-TACE and 125 I radioactive seeds results in a better overall survival than LBP-TACE therapy alone; thus, a comprehensive therapy is recommended for these patients 13 . The present study indicates that LBP causes significant apoptosis and inhibition of proliferation in HCC cells, similar to that observed in 125 I seed RT alone, whereas a combination of the two treatments results in an even greater effect in vitro and in vivo. These results indicate that LBP promotes 125 I-induced apoptosis and inhibition of proliferation in HCC.
A possible pathway involved in the 125 I-mediated apoptosis and inhibition of proliferation in HCC cells could be the PERK-eIF2α-ATF4-CHOP pathway. The activated PERK elicits UPR-related pro-apoptotic signals, markedly elevating the levels of phosphorylated eIF2α. I-induced apoptosis and anti-proliferation effect. All the experiments were performed in triplicate and the data are presented as the mean ± SD. The t-test was used for data analysis. *P < 0.05, **P < 0.01
This results in the activation of a pro-adaptive signaling pathway via the inhibition of global protein synthesis and selective translation of ATF4, a transcription factor that regulates many genes related to the recovery of cells and their adaption to stress 24 . However, ATF4 was found to be related to 5-fluorouracil resistance in colorectal cancer 25 . Interestingly, the ATF4 levels were upregulated after treatment with gemcitabine in pancreatic cancer cells and could be regarded as a mechanism for induction of apoptosis 26 . Furthermore, ATF4 increases the expression levels of transcription factor CHOP. Overexpression of CHOP downregulates the expression of Bcl-2, upregulates Bax, and evokes apoptosis 7 . In addition, CHOP plays an important role in another pro-apoptotic mechanism, because it directly activates the growth arrest and DNA damage-inducible protein, GADD34, which sufficiently promotes the dephosphorylation of eIF2α and reboots protein translation in stressed cells 27 . Our results showed that 125 I upregulated the PERK-eIF2α-ATF4-CHOP pathway in a dose-dependent manner. Besides, the apoptosis induced by 125 I was reduced when PERK was downregulated by PERK-siRNA. More importantly, not only did LBP enhance the upregulation of the PERK pathway induced by 125 I, the inhibition of tumor growth in mouse tumor model treated with combined treatment was compromised when PERK-siRNA was transfected into HCC cells, which might explain the mechanism by which LBP promotes the radiosensitivity of HCC cells to 125 I. Our results also show that LBP significantly increased the 125 I-induced cell cycle arrest in HepG2 cells. The ratio of cells in the G2/M stage in the combination treatment group was markedly higher than that in the 125 I seed radiation group. Univariate general linear model analysis showed that the arrest of HCC cells was greater in the combination treatment group than in the groups treated with either of the agents alone, indicating that LBP might have a synergistic effect with 125 I seeds. Dai et al. 8 reported that cell cycle arrest might be associated with the downregulation of CDK1, phosphorylated CDK1 (p-CDK1), cyclin B, CDC25C, p-CDK4, Rb, p-Rb, and E2F, and the upregulation of p27, p21, and p53 8 . Besides, cells I and LBP, the cell cycle (b), Bax/Bcl-2 ratio (c), and Annexin V-APC/PI assay (d) were performed to verify the rescue effect on apoptosis and antiproliferation. All the experiments were performed in triplicate and the data are presented as the mean ± SD. The t-test was used for data analysis. *P < 0.05, **P < 0.01 at G2/M are more sensitive to radiation, which might explain the ability of LBP to promote radiosensitivity of HCC cells to 125 I seeds. The data in this study indicate that LBP promotes the radiosensitivity of HCC cells to radioactive 125 I seeds. In addition, when comparing the radiosensitivity of HepG2 and SMMC7721 cells with 125 I seeds, it is interesting to find that the latter are more sensitive to 125 I seeds. The sensitization enhancement ratio for HepG2 and SMMC7721 was 1.37 and 1.63, respectively, indicating that a lower dose could be used to kill hepatic cancer cells when 125 I seed radiation is combined with concurrent LBP chemotherapy. We believe that the different effect between the two cell lines could be due to the different expression levels of ZHX2. ZHX2 has been reported to function as a tumor suppressor in the development of HCC and the reduced ZHX2 level also leads to a lower response to chemotherapeutic drugs [28] [29] [30] . Thus, further study is needed to investigate the link between 125 I seeds, radiosensitivity, and ZXH2 ZHX2.
Conclusion
In summary, the data in this study reveal a relationship between 125 I, LBP, and the PERK-eIF2α-ATF4-CHOP pathway. LBP promotes 125 I-induced apoptosis and inhibition of proliferation of HCC by upregulating the PERKeIF2α-ATF4-CHOP pathway. Furthermore, our data lays a solid foundation for better clinical application of this combined therapy.
